CALIFORNIA | LOCAL
August 15, 1999 |
To many veterans, the cascade of scourges has a biblical quality: Post-traumatic stress disorder. Agent Orange. Birth defects. Gulf War syndrome. Now there is hepatitis C. The chronic liver ailment turns up in ex-service personnel who use VA facilities--especially Vietnam-era vets--at a rate four times the national average, medical experts say.
September 1, 2003 |
Of the millions of Americans infected with hepatitis C, only half respond to treatment. The others live with the constant threat that their health may suddenly, and fatally, deteriorate. A new drug could improve those odds. When used with the antiviral drug interferon, a medication called Zadaxin may help thousands of patients better fight the disease. "This medication looks promising for people who don't respond to other drugs," says Dr.
May 14, 1995 |
The incidence of new hepatitis C infections among intravenous drug abusers has dropped unexpectedly by a dramatic 80% since 1990, according to preliminary results from the Centers for Disease Control and Prevention. Transmission of the virus among drug abusers is thought to account for as much as 85% of the hepatitis C infections discovered each year--a number that totaled 150,000 in 1990.
June 17, 1998 |
Schering-Plough Corp. said Tuesday it is seeking U.S. regulatory approval to sell its combination hepatitis C therapy to a wider group of patients, including those who haven't been treated already with standard hepatitis-fighting drugs. The news follows an announcement last month that the combination of drugs developed by Schering-Plough and Costa Mesa-based ICN Pharmaceuticals Inc. offers significant benefits to previously untreated patients.
December 10, 1998 |
Schering-Plough Corp. and ICN Pharmaceuticals Inc. won regulatory approval Wednesday to sell their combination hepatitis C treatment to a wider group of patients. The Food and Drug Administration approved the combination therapy known as Rebetron for use in patients who haven't been treated already with standard hepatitis-fighting drugs. The wider use should boost sales for Schering-Plough, the eighth biggest U.S. drug maker, and Costa Mesa-based ICN, Eastern Europe's largest drug maker.
August 17, 2001 |
ICN Pharmaceuticals Inc.'s ribavirin drug, used in combination with a Schering-Plough Corp. drug to treat hepatitis C, may face generic competition within a year if an unidentified company wins Food and Drug Administration approval for its version. The FDA's Web site said the agency has received a request from a company to sell a generic version of ribavirin, which is sold by Schering-Plough with its own hepatitis C drugs Intron A and Peg-Intron.
June 4, 1998 |
Schering-Plough Corp. and ICN Pharmaceuticals Inc. won Food and Drug Administration approval Wednesday to sell their combination treatment for hepatitis C patients who suffer a relapse. The combination includes Intron-A, which Schering-Plough already sells alone to treat hepatitis, and ICN's drug ribavirin, or Rebetol. Studies have shown the two drugs together provide a significant benefit to patients.
April 10, 2008 |
Abu Ubaida al Masri, a suspected mastermind of Al Qaeda plots including the London transportation bombings of 2005, has died of an infectious disease in Pakistan, Western anti-terrorism officials said Wednesday. The Egyptian militant is thought to have died of hepatitis C, a U.S. anti-terrorism official said.
March 21, 2014 |
U.S. lawmakers have asked Gilead Sciences Inc. to justify the price of its new $84,000 drug for hepatitis C patients amid growing concern about the high cost to taxpayers and consumers. In a letter to the Foster City, Calif., company, Rep. Henry A. Waxman (D-Beverly Hills) and two other Democratic lawmakers asked Gilead Chief Executive John C. Martin to explain the rationale for selling Sovaldi for $1,000 per pill. Medical experts say previous therapies for hepatitis C helped only about half of patients and had numerous side effects, such as flu-like symptoms, anemia and depression.